Literature DB >> 29661789

Late mortality after autologous blood or marrow transplantation in childhood: a Blood or Marrow Transplant Survivor Study-2 report.

Anna Sällfors Holmqvist1,2, Yanjun Chen3, Jessica Wu3, Kevin Battles3, Ravi Bhatia4, Liton Francisco3, Lindsey Hageman3, Michelle Kung3, Emily Ness3, Mariel Parman3, Donna Salzman4, Jeanette Falck Winther5,6, Joseph Rosenthal7, Stephen J Forman7, Daniel J Weisdorf8, Mukta Arora8, Saro H Armenian7, Smita Bhatia3.   

Abstract

Autologous blood or marrow transplantation (BMT) is a curative option for several types of childhood cancer. However, there is little information regarding the risk of late mortality. We examined all-cause mortality, relapse-related mortality (RRM), and nonrelapse-related mortality (NRM) in 2-year survivors of autologous BMT performed before age 22 between 1980 and 2010 at 1 of 2 US transplant centers. Vital status information was collected using medical records, National Death Index, and Accurint databases. Overall survival was calculated using Kaplan-Meier techniques. Cumulative incidence of mortality used competing risk methods. Standardized mortality ratio (SMR) was calculated using age-, sex-, and calendar-specific mortality rates from Centers for Disease Control and Prevention. Cox regression analysis was used to determine predictors of all-cause late mortality. Among the 345 2-year survivors, 103 deaths were observed, yielding an overall survival of 70.3% 15 years post-BMT. The leading causes of death included primary disease (50.0%), subsequent neoplasm (21.4%), and infection (18.2%). Overall, the cohort was at a 22-fold increased risk of late mortality (SMR, 21.8; 95% CI, 17.9-26.3), compared with the general population. Mortality rates remained elevated among the 10-year survivors (SMR, 20.6; 95% CI, 9.9-37.2) but approached those of the general population ≥15 years post-BMT. The 10-year cumulative incidence of RRM (14.3%) exceeded that of NRM (10.4%). The 10-year cumulative mortality rate declined over time (<1990, 35.1%; 1990-1999, 25.6%; 2000-2010, 21.8%; P = .05). In conclusion, childhood autologous BMT recipients have an increased risk of late mortality, compared with the general population. The late mortality rates have declined over the past 3 decades.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2018        PMID: 29661789      PMCID: PMC6032893          DOI: 10.1182/blood-2018-02-831156

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Problems with proper completion and accuracy of the cause-of-death statement.

Authors:  A E Smith Sehdev; G M Hutchins
Journal:  Arch Intern Med       Date:  2001-01-22

2.  Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries.

Authors:  T R Möller; S Garwicz; L Barlow; J F Winther; E Glattre; G Olafsdottir; J H Olsen; R Perfekt; A Ritvanen; R Sankila; H Tulinius
Journal:  J Clin Oncol       Date:  2001-07-01       Impact factor: 44.544

3.  Myeloablative therapy with autologous stem cell rescue for patients with Ewing sarcoma.

Authors:  S L Gardner; J Carreras; C Boudreau; B M Camitta; R H Adams; A R Chen; S M Davies; J R Edwards; A C Grovas; G A Hale; H M Lazarus; M Arora; P J Stiff; M Eapen
Journal:  Bone Marrow Transplant       Date:  2008-02-04       Impact factor: 5.483

4.  A population-based cohort study of late mortality in adult autologous hematopoietic stem cell transplant recipients in Australia.

Authors:  Lesley J Ashton; Renate E Le Marsney; Anthony J Dodds; Ian Nivison-Smith; Leonie Wilcox; Tracey A O'Brien; Claire M Vajdic
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-13       Impact factor: 5.742

5.  Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study.

Authors:  Smita Bhatia; Leslie L Robison; Liton Francisco; Andrea Carter; Yan Liu; Marcia Grant; K Scott Baker; Henry Fung; James G Gurney; Philip B McGlave; Auayporn Nademanee; Norma K C Ramsay; Anthony Stein; Daniel J Weisdorf; Stephen J Forman
Journal:  Blood       Date:  2005-02-08       Impact factor: 22.113

Review 6.  Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors.

Authors:  A Marachelian; A Butturini; J Finlay
Journal:  Bone Marrow Transplant       Date:  2008-01-07       Impact factor: 5.483

Review 7.  Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report.

Authors:  Eric J Chow; Lynnette Anderson; K Scott Baker; Smita Bhatia; Gregory M T Guilcher; Jennifer T Huang; Wendy Pelletier; Joanna L Perkins; Linda S Rivard; Tal Schechter; Ami J Shah; Karla D Wilson; Kenneth Wong; Satkiran S Grewal; Saro H Armenian; Lillian R Meacham; Daniel A Mulrooney; Sharon M Castellino
Journal:  Biol Blood Marrow Transplant       Date:  2016-01-21       Impact factor: 5.742

8.  Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation.

Authors:  Paul J Martin; George W Counts; Frederick R Appelbaum; Stephanie J Lee; Jean E Sanders; H Joachim Deeg; Mary E D Flowers; Karen L Syrjala; John A Hansen; Rainer F Storb; Barry E Storer
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

9.  Late mortality after hematopoietic SCT for a childhood malignancy.

Authors:  T Schechter; J D Pole; D Darmawikarta; J Doyle; M Ali; M Egeler; A Gassas; M S Irwin; M Greenberg; P C Nathan
Journal:  Bone Marrow Transplant       Date:  2013-05-13       Impact factor: 5.483

  9 in total
  4 in total

1.  Trends in Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplantation Over Three Decades: A BMTSS Report.

Authors:  Smita Bhatia; Chen Dai; Wendy Landier; Lindsey Hageman; Jessica Wu; Elizabeth Schlichting; Arianna Siler; Erin Funk; Jessica Hicks; Shawn Lim; Nora Balas; Alysia Bosworth; Hok Sreng Te; Liton Francisco; Ravi Bhatia; Donna Salzman; Frederick D Goldman; Stephen J Forman; Daniel J Weisdorf; F Lennie Wong; Saro H Armenian; Mukta Arora
Journal:  J Clin Oncol       Date:  2022-03-09       Impact factor: 50.717

2.  Survivorship after Autologous Hematopoietic Cell Transplantation for Lymphoma and Multiple Myeloma: Late Effects and Quality of Life.

Authors:  George E Georges; Merav Bar; Lynn Onstad; Jean C Yi; Mazyar Shadman; Mary E Flowers; Paul A Carpenter; Susan Stewart; Stephanie J Lee; Leona A Holmberg
Journal:  Biol Blood Marrow Transplant       Date:  2019-10-09       Impact factor: 5.742

3.  Candidacy for Extracorporeal Life Support in Children After Hematopoietic Cell Transplantation: A Position Paper From the Pediatric Acute Lung Injury and Sepsis Investigators Network's Hematopoietic Cell Transplant and Cancer Immunotherapy Subgroup.

Authors:  Matt S Zinter; Jennifer McArthur; Christine Duncan; Roberta Adams; Erin Kreml; Heidi Dalton; Hisham Abdel-Azim; Courtney M Rowan; Shira J Gertz; Kris M Mahadeo; Adrienne G Randolph; Prakadeshwari Rajapreyar; Marie E Steiner; Leslie Lehmann
Journal:  Pediatr Crit Care Med       Date:  2022-03-01       Impact factor: 3.624

4.  Sickle Cell Transplantation Evaluation of Long-term and Late Effects Registry (STELLAR) to Compare Long-term Outcomes After Hematopoietic Cell Transplantation to Those in Siblings Without Sickle Cell Disease and in Nontransplanted Individuals With Sickle Cell Disease: Design and Feasibility Study.

Authors:  Lakshmanan Krishnamurti; Staci D Arnold; Ann Haight; Allistair Abraham; Gregory Mt Guilcher; Tami John; Nitya Bakshi; Shalini Shenoy; Karen Syrjala; Paul L Martin; Sonali Chaudhury; Gretchen Eames; Olusola Festus Olowoselu; Matthew Hsieh; Josu De La Fuente; Kimberly A Kasow; Elizabeth Stenger; Anne Mertens; Fuad El-Rassi; Peter Lane; Bronwen E Shaw; Lillian Meacham; David Archer
Journal:  JMIR Res Protoc       Date:  2022-07-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.